Delivery Order SPE2DB20D3103-SPE2DB26FL5K9
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $3,760.29 to AmerisourceBergen Drug Corp for OPZELURA 1.5% Cream (60gm), a topical pharmaceutical product. This firm fixed-price, non-set-aside contract was awarded on August 15, 2025, with an ultimate completion date of August 18, 2025. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $2,503.51 to AmerisourceBergen Drug Corp for OPZELURA 1.5% Cream in 60-gram quantities under a firm fixed-price contract. The award was made on August 28, 2025, with an ultimate completion date of August 29, 2025, with no set-aside designation applied. Performance will take place at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $5,650.79 on September 15, 2025, for OPZELURA 1.5% Cream in 60-gram quantities, with final delivery scheduled by September 16, 2025. This non-competitive, firm fixed-price delivery order represents a routine pharmaceutical procurement under the company's existing contract vehicle. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for OPZELURA 1.5% Cream (60 grams) valued at $5,888.90 with a firm fixed price structure. This is a non-set-aside competitive award executed as a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with the Defense Logistics Agency Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle running through...
- The Defense Logistics Agency awarded a $3,199.78 delivery order to AmerisourceBergen Drug Corp for OPZELURA 1.5% Cream (60GM), a pharmaceutical product to be delivered to the Conshohocken, Pennsylvania location. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is classified as a delivery order with an ultimate completion date of July 23, 2025. The award represents a discrete transaction under AmerisourceBergen's broader contracting relationship with the...
- The Defense Logistics Agency awarded a delivery order valued at $8,242.10 to AmerisourceBergen Drug Corp for OPZELURA 1.5% cream (60GM) on October 29, 2025, with an ultimate completion date of October 30, 2025. This competitively awarded, firm fixed-price delivery order represents a small-value pharmaceutical procurement executed through the company's existing indefinite delivery contract with DLA. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order valued at $5,875.38 to AmerisourceBergen Drug Corp for OPZELURA 1.5% Cream (60GM) on July 21, 2025, with an ultimate completion date of July 22, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract falls under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- The Defense Logistics Agency awarded a delivery order valued at $2,909.76 to AmerisourceBergen Drug Corp for OPZELURA 1.5% Cream (60GM), a topical pharmaceutical product. This non-set-aside, competitively awarded contract features firm fixed pricing and was executed on July 18, 2025, with an ultimate completion date of July 21, 2025. The order will be fulfilled from AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on September 4, 2025, by the Defense Logistics Agency for the supply of Opzelura 1.5% Cream in 60-gram units. The contract, valued at $1,310.45, carries a firm fixed price and an ultimate completion date of September 5, 2025. This delivery order represents a non-set-aside competitive award and is executed under AmerisourceBergen's larger Indefinite Delivery...
- Amerisourcebergen Drug Corp has received a $5,871.87 firm fixed price delivery order from the Defense Logistics Agency (DLA) Troop Support Medical to supply OPZELURA 1.5% cream in 60gm quantities. Performance will take place at Amerisourcebergen's headquarters in Conshohocken, Pennsylvania, with all supplies delivered by November 24, 2023. As a leading pharmaceutical distributor, Amerisourcebergen Drug Corp regularly obtains delivery orders against its indefinite delivery contract with DLA Troop...
- SPE2DB20D3103Indefinite Delivery Contract
- SPE2DB20D3103-SPE2DB26FL5K9Delivery Order
The Defense Logistics Agency awarded a $6,838.42 delivery order to AmerisourceBergen Drug Corp for OPZELURA 1.5% cream (60 GM) on November 7, 2025, with completion targeted for November 10, 2025. This non-set-aside, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.9 billion pharmaceutical supply agreement running through December 2026. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical federal medical procurement vendor for military and veteran healthcare systems. The company maintains an extensive portfolio of pharmaceutical deliveries through competitive federal contracting, supplying brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains. The underlying SPE2DX vehicle enables the company to provide comprehensive global pharmaceutical support to the Defense Health Agency, U.S. Coast Guard, and other government healthcare systems, with DLA planning to establish next-generation Pharmaceutical Prime Vendor Global Program contracts involving multiple regional awards and contractors.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.8k | 11/7/25 |